Qing Zhou-Liu

Title: Inventor Qing Zhou-Liu: Pioneering Advances in High-Throughput Screening

Introduction

Qing Zhou-Liu, based in Chennevières-sur-Marne, France, is an accomplished inventor known for his impactful contributions to the field of biotechnology. With a focus on nematode acetylcholine receptors, his innovative work has the potential to revolutionize how compounds are screened for parasiticidal properties.

Latest Patents

Qing Zhou-Liu holds a patent titled "Mammalian cell lines expressing functional nematode acetylcholine receptors and use thereof for high-throughput screening assays." This patent discloses mammalian cell lines that stably express functional nematode acetylcholine receptor subunits. The expression of functional ion channels is achieved through the stable co-expression of the chaperone protein, RIC3. These cell lines are instrumental for high-throughput screening (HTS) assays designed to identify new candidate parasiticidal and nematocidal active ingredients.

Career Highlights

Throughout his career, Qing Zhou-Liu has made significant strides in pharmaceutical and biotechnology sectors. Notably, he has worked with prestigious companies such as Boehringer Ingelheim Animal Health, Inc. and Sanofi. His expertise in expressing functional receptors has been a key element of his work, enhancing the capabilities of drug discovery processes.

Collaborations

Qing has collaborated with renowned professionals in his field, including Lance Hammerland and Brenda Bondesen. Their combined efforts have contributed to advancements in high-throughput screening technologies, facilitating the identification of effective treatments against parasitic infections.

Conclusion

In summary, Qing Zhou-Liu stands out as a notable inventor in the realm of biotechnology. His patent on mammalian cell lines expressing nematode acetylcholine receptors not only demonstrates his innovative spirit but also highlights the potential for significant advancements in parasiticidal compound screening. Through his collaborations and work with leading companies, he continues to pave the way for breakthroughs in drug development.